Sulfadiazine Powder acts as a sulfonamide antibiotic, inhibiting bacterial folic acid synthesis by competitively blocking dihydropteroate synthetase. This enzyme is crucial for the production of tetrahydrofolic acid, an essential precursor for bacterial DNA and protein synthesis.
In microbiology, Sulfadiazine Powder is pivotal for formulating culture media, enabling selective inhibition of bacterial growth for isolating and identifying specific strains.
Sulfadiazine’s broad spectrum of activity encompasses various bacteria, including both Gram-positive and Gram-negative organisms. Clinically, Sulfadiazine powder treats infections caused by Escherichia coli, Streptococcus pneumoniae, and Staphylococcus aureus.
In antimicrobial susceptibility testing, Sulfadiazine’s effectiveness is measured by determining the Minimum Inhibitory Concentration (MIC) of bacterial isolates.
Moreover, Sulfadiazine Powder is a valuable tool in researching antibiotic resistance mechanisms. By exposing bacteria to Sulfadiazine, scientists uncover pathways through which resistance develops, aiding in combating resistance.
Cat. Number | AS-2020 |
CAS Number | 68-35-9 |
MDL Number | MFCD00006065 |
Pubchem | 310280373 |
Molecular Weight | 250.28 g/mol |
Molecular Formula | C10H10N4O2S |
Storage Temperature | 20°C |
Form and Color | Powder, white to yellow |
Assay (on dry basis) | 99 – 101% |
Loss on Drying | Max. 0.5% |
Sulfated ash | ≤ 0.1% |
Heavy metals | ≤ 20 ppm |